Bordetella Pertussis

• Uses: For the temporary relief of minor chest congestion and cough due to mucus build-upICD-10: R05.9

DIRECTIONS At first sign of symptoms: Adults and children 4 years and older: 1 tablet every 1/2 to 1 hour until symptoms lessen, then continue with standard dosage. Standard dosage: Adults and children 4 years and older : Take 1-2 tablets every 4 to 6 hours. Do not exceed 12 tablets in 24 hours. For children under 4, consult your health professional. Allow tablets to dissolve completely in the mouth, do not swallow.

WARNINGS

Recent PubMed references pinned to Bordetella Pertussis as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Bordetella pertussis pneumonia in adults: two case reports and diagnostic challenges.
  Journal of infection in developing countries · 2026 · Deng L, Hu Z, Wang J, et al.
  PMID 42112728DOI 10.3855/jidc.20988
• Mechanisms of natural and vaccine-induced immunity to Bordetella pertussis.
  PLoS pathogens · 2026 · Borkner L, Sutton CE, Udayan S, et al.
  PMID 42030347DOI 10.1371/journal.ppat.1014128
• Modeling neonatal immune response to B. pertussis identifies early B cell activation and differentiation.
  PLoS pathogens · 2026 · Matczak S, Sadi M, Leroux P, et al.
  PMID 42018590DOI 10.1371/journal.ppat.1014163
• [Investigation on the incidence of pertussis and the carriage and distribution characteristics of Bordetella pertussis among healthy individuals in certain regions of Xinjiang Uygur Autonomous Region from 2023 to 2024].
  Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] · 2026 · Tian T, Fu WH, Li J, et al.
  PMID 41991286DOI 10.3760/cma.j.cn112150-20250508-00405
• Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis.
  The Journal of antimicrobial chemotherapy · 2026 · Chen J, Liang G
  PMID 41988658DOI 10.1093/jac/dkag131
• Multiparametric analysis of vaccine-induced B and T cell responses for optimal evaluation of memory immune responses to Bordetella pertussis in children.
  Vaccine · 2026 · Smet J, Smits K, Dirix V, et al.
  PMID 41967190DOI 10.1016/j.vaccine.2026.128552
• Longitudinal assessment of asymptomatic infection of Bordetella pertussis among pertussis acellular vaccinated adolescents.
  Vaccine · 2026 · Brown NE, Pawloski LC, Winter K, et al.
  PMID 41967186DOI 10.1016/j.vaccine.2026.128567
• Clinical epidemiological characteristics and risk factors for severe pertussis in children in Xiamen.
  BMC infectious diseases · 2026 · Zhang J, Su D, Xu Y, et al.
  PMID 41963827DOI 10.1186/s12879-026-13255-0

The 10 most recently updated of 195 ClinicalTrials.gov registrations naming Bordetella Pertussis as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
  Recruiting · Phase 3 · Interventional · 6,000 enrolled · Pfizer
  NCT07160244updated 2026-06-09
• Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months Old
  Not yet recruiting · Phase 4 · Interventional · 320 enrolled · Chiang Mai University
  NCT07621341updated 2026-06-02
• Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial
  Active not recruiting · Phase 4 · Interventional · 5,000 enrolled · National Cancer Institute (NCI)
  NCT05237947updated 2026-05-28
• Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks
  Recruiting · Interventional · 72 enrolled · University of Southampton
  NCT05847322updated 2026-05-18
• A Phase 4, Randomised Vaccination Study in Healthy Adults to Investigate the Effects of Acellular Pertussis Vaccine on Colonisation With Bordetella Pertussis Using Controlled Human Infection
  Active not recruiting · Phase 4 · Interventional · 99 enrolled · Dimitri Diavatopoulos
  NCT06903221updated 2026-05-07
• Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines
  Active not recruiting · Phase 4 · Interventional · 25 enrolled · Washington University School of Medicine
  NCT07493460updated 2026-04-22
• Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses
  Active not recruiting · Interventional · 1,000 enrolled · University of Nebraska
  NCT05864118updated 2026-04-17
• Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  Completed · Phase 2 · Interventional · 42 enrolled · Jennifer Woyach
  NCT02518555updated 2026-04-06
• Safety Monitoring of Boostagen® Vaccine in Thailand
  Completed · Observational · 10,727 enrolled · BioNet-Asia Co., Ltd.
  NCT07444502updated 2026-03-03
• Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
  Completed · Phase 1 · Interventional · 54 enrolled · Institut National de la Santé Et de la Recherche Médicale, France
  NCT02453048updated 2026-02-27

Frequently asked questions

What is Bordetella Pertussis used for?

According to FDA labeling, Bordetella Pertussis carries indications including: Uses: For the temporary relief of minor chest congestion and cough due to mucus build-up. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.